Zusammenfassung. Patientenorientierung schließt die Berücksichtigung von Therapiezielpräferenzen ein. Shared decision making kann dazu beitragen, die Therapiezufriedenheit und -mitarbeit zu verbessern. Fragestellungen: 1) Bestimmung, der von Patienten priorisierten Therapieziele in der Behandlung bipolarer Störungen, 2) Extraktion der wichtigsten Therapiezieldimensionen, 3) Darstellung von Unterschieden in der Wichtigkeit abhängig von Geschlecht, Alter und Behandlungsstatus. Im Rahmen einer BMBF-geförderten Studie wurde die Wichtigkeit (1 = unwichtig bis 5 = sehr wichtig) von 73 Therapiezielen in der Behandlung bipolarer Störungen aus Betroffenensicht (N = 333) untersucht. Störungsbewältigung (R2 = 29 %), Lebensqualität (R2 = 9 %), Beteiligung am therapeutischen Geschehen (R2 = 7 %) und Nebenwirkungen von Medikamenten (R2 = 5 %) stellten die bedeutsamsten Zieldimensionen dar. Morbiditätsparameter (Symptome, Episoden) hatten dagegen einen geringeren Stellwert (R2 = 3,6 %). Die Wichtigkeitseinschätzungen variierten in Abhängigkeit von Geschlecht, Alter und Behandlungsstatus. In der Behandlung von bipolaren Störungen legen Patienten vor allem Wert auf die Bearbeitung störungsbezogener Probleme sowie die Verbesserung von Lebensqualität. Durch eine verstärkte Orientierung an Bedürfnissen von bipolar Betroffenen auf Seiten ihrer Behandler lassen sich Prozesse des shared decision making optimieren.
Highlights
Proteinaceous nanocapsules (NCs) with a narrow size distribution could be prepared.
NCs with biocompatible oil cores could be produced avoiding toxic cross-linkers.
WGA as a targeter molecule was embedded in the proteinaceous particle shell.
WGA-modified NCs could be used for tumor targeting.
ObjectiveHopelessness and depression are strongly associated with suicidality. Given that physical and psychological outcomes can be altered with hope, hope is a therapeutic goal of increasing importance in the treatment of brain tumor patients. Moreover, it is not yet understood which factors affect the perception of hope in brain tumor patients. In addition, it remains uncertain whether lower-grade brain tumor patients suffer less from psycho-oncological distress than higher-grade brain tumor patients.MethodsNeuro-oncological patients were examined perioperatively with the Distress Thermometer (DT) and the Herth Hope Index (HHI). In addition, psychological comorbidities (anxiety GAD-2, depression PHQ-2) and an assessment of general psycho-oncological distress were recorded.ResultsSixty-six brain tumor patients were included (median age 53 years, 35% higher-grade brain tumors, i.e., WHO grade III/IV). No differences between higher- and lower-grade brain tumor patients were observed for general psycho-oncological distress and hope. However, higher-grade brain tumor patients showed a significantly higher level of depression (p ≤ 0.001) and more negative expectations regarding therapeutic success (H = 4.873, p ≤ 0.050). The extent of depression correlated negatively with hope.ConclusionUnexpectedly, higher-grade brain tumor patients remained as hopeful as lower-grade brain tumor patients despite the devastating diagnosis, higher levels of depression, and a worse expectation of therapeutic success. Conversely, lower-grade brain tumor patients experience as much psycho-oncological distress as patients with a higher-grade brain tumor, underpinning the imperative need for comprehensive psycho-oncological screening. For all brain tumor patients, considering hope is important to avoid suicides resulting from hopelessness and depression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.